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ABSTRACT
Chronic graft-versus-host disease (cGVHD) is amajor complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT) and a leading cause of non-relapse mortality (NRM). Currently, biology-based markers are
lacking both for diagnosis and formonitoring the activity of cGVHD. Seventy patients who receivedHSCTwere
enrolled in a pilot study, including 21 without cGVHD and 49 with active or resolved cGVHD. Evaluations were
comprised of clinical parameters including cGVHD severity and infections. Peripheral blood cells were analyzed
by multi-parameter flow cytometry. The CD191 B cell compartment was further subdivided by staining for sur-
face IgD, CD21 andCD27.No significant differences in absolute B, T, and natural killer (NK) cell numbers were
observed between the groups with and without cGVHD. However, elevated numbers (.15% of B lymphocytes)
of immature/transitional CD191/CD21- B cells were associated with the occurrence of severe infections (P 5
.003).Most significantly, all patients with active cGVHD and elevated numbers of CD191/CD21- B lymphocytes
experienced severe infections (P5 .00016). The numbers of both non-class-switched and class-switched mem-
ory B cells were significantly lower in patients with active cGVHD when compared to patients who never expe-
rienced cGVHD (P5 .002 and P5 .001). Perturbation of circulating B lymphocyte compartments may serve as
a novel biomarker for monitoring cGVHD activity and its impact on the immune system. A prospective study on
unselected patients assessed serially for B cell reconstitution after HSCT is warranted.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
chronic GVHD  immature/transitional and memory B lymphocytesINTRODUCTION
Chronic graft-versus-host disease (cGVHD) is
a major late complication of allogeneic hematopoietic
stem cell transplantation (HSCT) and occurs in 30%
to 80% of patients [1]. It varies in severity and clinical
course; cGVHD is the leading cause of nonrelapse
mortality (NRM) more than 2 years after transplanta-
tion [2,3]. After HSCT, immune reconstitution occurs
gradually over time [4,5]. Immune reconstitution is
known to be slower for human leukocyte antigen208(HLA)-mismatched [6] or T cell depleted grafts [7],
and in survivors with cGVHD [8].
The pathophysiology of cGVHD is still poorly
understood [9]. The importance of autoreactivity is
suggested by clinical manifestations of cGVHD that
frequently mimic those of autoimmune diseases [10],
and by the finding of auto-antibodies derived from
B cells after T helper type 2 (TH2) mediated stimula-
tion and cytokine release [11]. Recently, chimeric anti-
CD20-antibody therapy was reported to be effective
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distinct B cells or B cell subsets might be directly path-
ogenic in cGVHD [12,13]. Another probable mecha-
nism for cGVHD is dysfunctional T cell selection in
the thymus inducing autoimmune diseases [14]. Func-
tional asplenia, with elevated numbers of erythrocytes
bearing Howell-Jolly bodies (HJ) as the hallmark, was
observed in patients with cGVHD [15]. Asplenia also
affects homeostasis of memory B lymphocytes circu-
lating in the peripheral blood (PB) [16].
In general, B cell development is a stepwise pro-
cess. B cell precursors are generated in the bone mar-
row (BM) and migrate to the periphery at the
immature/transitional CD191/CD21- B cell stage
when they are still short-lived and functionally imma-
ture [17]. Immature/transitional B cells are trans-
ported via the blood vessels to the spleen, where they
develop into long-lived mature B cells (CD191/
CD211). This developmental step is critically depen-
dent on the presence of a mature B cell receptor [18]
and on tightly regulated additional survival signals
brought about by transmembrane proteins such as B
cell activation factor from the tumor necrosis factor
family (BAFF) [19]. Mature B cells re-circulate
between the lymphoid follicles of spleen and lymph
nodes, and they play a major role in the adaptive im-
mune response. Significantly, in the initial phases of
infection and before specific antibody production
commences, natural antibodies limit the spread of
pathogens. Subsequently, the antigen-specific, neu-
tralizing antibody response clears cytopathic infec-
tions [20]. In fact, all vaccines that are clinically
efficient today are dependent on neutralizing antibody
responses (rather than T cell-mediated immunity).
This demonstrates the unique importance of B cells
and their products for protective immunity [20].
Hence, the in-depth analysis of the composition of
major B cell sub-populations within a group of patients
who underwent HSCT should provide important
insights into the patients’ level of clinically relevant
protective immunity and thus, their overall immuno-
competence. This knowledge would especially be
warranted in situations where the post-transplant im-
mune system is compromised by ongoing immune
responses, such as in cGVHD.
We performed a pilot trial to analyze leukocyte
populations in PB and we focused on the homeostasis
of major B cell subpopulations.We studiedCD21 neg-
ative immature/transitional B lymphocytes [21,22],
which are known to be increased in autoimmune dis-
eases, ie SLE [23], and in primary and secondary
immunodeficiencies, such as common variable immu-
nodeficiency [24] and advanced stages of HIV [25].
Furthermore, we analyzed the CD27 positive memory
B lymphocyte compartment, which harbors the direct
precursors of immunoglobulin secreting B cells
[26,27].No significant differences in absolute B, T, and
natural killer (NK) cell numbers between the groups
with and without cGVHD were seen. However, in
patients with .15% immature/transitional CD 191/
CD21- B cells, significantly more severe infections
after HSCT were observed as compared to patients
with low CD191/CD21- B cell counts. The number
of both class-switched and non-class-switched mem-
ory B cells was significantly lower in patients with
active cGVHD compared to patients never experienc-
ing cGVHD in our pilot study. In summary, B lym-
phocyte subsets might represent novel biomarkers
for the assessment of cGVHD activity and its impact
on the immune system seen as increased susceptibility
to severe infections. Our preliminary findings should
be evaluated prospectively in patients after HSCT.
METHODS
Trial Conduct
During February 2005, all patients with active
cGVHD from the Outpatient Clinic of the Bone
Marrow Transplant (BMT) Facility who had routine
follow-up visits were asked participate. Study inclu-
sion criteria were complete multi lineage donor cell
engraftment, being at least 100 days after allogeneic
HSCT, available data on all follow-up visits since dis-
charge after HSCT, and written informed consent.
Of these 26 patients sampled, 4 were later considered
to have resolved cGVHD at the time of sampling
whereas 22 had active cGVHD. After observing the
disturbance in B cell homeostasis another 44 patients
were asked to join the study in September 2005 and
they participated after signing the informed consent.
This group included 13 patients with active cGVHD,
10 with resolved cGVHD, and 21 who had never ex-
perienced cGVHD. All of these patients were seen in
the Outpatient Clinic of the BMT Facility for routine
follow-up visits. During the sampling period of Feb-
ruary to September 2005, only the following patients
were excluded: those who missed follow-up visits;
were unable to understand the germane informed
consent; refused to participate in the study; with un-
measurably low B-cell numbers; or with a relapse of
hematological disease. A total of 70 patients were en-
rolled into this pilot study that had been approved by
the local institutional review board (IRB). The study
was conducted in accordance with the declaration of
Helsinki. In addition to the analysis of leukocyte sub-
populations, blood counts, C-reactive protein, and
serum immunoglobulin levels were assessed during
routine follow-up examinations of patients. Examina-
tions were done at least weekly during the first 100
days after HSCT, monthly until day 365 after
HSCT, then every 3 months for 2 years, followed
by every 6 months thereafter.
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repeated once (n57), twice (n513), three (n57), or
four (n59) times 6 to 27 months after the first analysis.
Three of these 36 patients had never had cGVHD; 8
patients had resolved cGVHD; and 25 patients had
active cGVHD.
The Infection Module of Common Toxicity Cri-
teria, National Cancer Institute [28], was used for
retrospective evaluation of the severity of infections
according to hospital records dating from HSCT un-
til study entry. Patients were stratified into those
with never or only mild infectious episodes (CTC
grades 0 to II); and severe ones (CTC grades III to
IV) requiring i.v. treatment and unexpected hospital-
ization or being life-threatening. In addition, in all
patients, all infectious episodes during the post-
transplant period (from day 0 of HSCT until first
B lymphocyte analysis) were collected retrospectively
and stratified according to clinically defined bacte-
rial, viral, or fungal infection. Clinically defined in-
fection was an infection that resulted in a change
of therapy with systemic antimicrobial agents or
suspected infection with supporting clinical or radio-
graphic findings. In cases of bacterial, viral, or fungal
infection, appropriate documentation of the organ-
ism had to be present.
Patients and Therapeutic Modalities
Transplant and patient characteristics are shown
in Tables 1 and 2. cGVHD was diagnosed according
to published criteria [2,9] and treatment response
was assessed according to the NIH Consensus Devel-
opment Project [29]. For the analysis, resolved
cGVHD was defined as the complete resolution of
all organ manifestations. The active cGVHD group
consisted of patients with partial resolution or progres-
sion of organ manifestations despite immunosuppres-
sive therapy. Figure 1 shows the time from HSCT
until first assessment of B cell subpopulations. In the
group never experiencing cGVHD, there was amedian
of 48 (range, 5 to 127) months compared to a median
of 62 (range, 10 to 150) months in the group with re-
solved cGVHD; and a median of 42 (range, 8 to 122)
months in the group with active cGVHD.
In the majority of patients, first-line treatment of
cGVHD consisted of prednisolone in combination
with a calcineurin inhibitor. Patients with cGVHD
were under anti-infective prophylaxis in accordance
with local guidelines: 1) antibiotic prophylaxis targeting
encapsulated bacteria, and 2) Pneumocystis carinii pro-
phylaxis as recommended [30]. In addition, antibiotic
prophylaxis before invasive procedures and i.v. immu-
noglobulins (Ig) in case of hypogammaglobulinemia
and recurrent severe infections was given to patients
with cGVHD [31].Isolation of Blood Cells, Immunophenotyping,
Flow Cytometry, and Fluorescein in situ
Hybridization of Sorted Cells
Optimal concentrations of directly conjugated
monoclonal antibodies (mAbs) were added to 50 ml of
whole blood, and incubated for 20 mins at room
temperature. Afterwards, 100 ml ADG-lysis solution
(An der Grub, Austria) was added, incubated for 10
mins, followed by hypotonic lysis of red blood cells in
H2O. Cells were collected by centrifugation; superna-
tant was discarded; cells were re-suspended in sheath
fluid at 4C (Becton Dickinson, Mountain View, CA)
and analyzed by acquiring 5  103 cells in the lympho-
gate for leukocyte subpopulations and 1-3  103
CD191 B cells for B cell subset analysis. Three-color
data acquisition was performed on a FACS Calibur
flow cytometer, supported by the Cell Quest software
(Becton Dickinson). Forward versus side scatter
parameters were used to gate on major leukocyte sub-
populations. We used mAbs CD3-APC (S4.1), CD16-
PE (3G8), CD19-FITC (SJ25-C1), CD21-PE (BU32),
CD56-PE (MEM-188), negative control IgG1-APC,
and goat affinity purified F(ab‘)2 anti-human IgD anti-
body from Caltag Laboratories (Burlingame, CA),
CD4-FITC (VIT4), CD8-PE (VIT8), CD14-PE
(MEM-18), CD45-FITC (VIT200), and negative con-
trol mAbs VIAP-FITC and 4H1-A7-PE from An der
Grub (Kaumberg, Austria) and CD69-FITC mAb
(L78) from Becton Dickinson (San Jose, CA). CD27-
FITC (VIT14) was kindly provided by Dr. Majdic.
FISHanalyseswere performedon cytospin preparations
of lymphoid subsets in patients after sex-mismatched
transplantation as previously described [32].
Statistical Analysis
Data were evaluated by the Fisher’s exact test. Sta-
tistical comparisons of numeric data were made using
either unpaired or paired Student’s t-test. Results
were considered statistically significant when Pwas be-
low .05.
A multiple logistic regression analysis for factors
impacting the occurrence of severe infections was per-
formed. In univariate analysis, the variables–‘‘occur-
rence of cGVHD, conditioning (myeloablative vs
reduced-intensity (RIC)), use of antithymocyte globu-
lin, hematopoietic stem cell source (BM vs peripheral
blood stem cells [PBSC]), patient age, immunosup-
pressive therapy (yes or no), steroid use (yes or no),
presence of HJ bodies, hypogammaglobulinemia (yes
or no), number of CD31, CD41, CD81, CD191,
CD191/CD21-, CD191/IgD1/CD271, CD191/
IgD-/CD271 cells, CD4/CD8 ratio, number of mono-
cytes and granulocytes at study entry’’–were assessed.
Covariates with a P-value under .10 were entered
into the multiple logistic regression analysis. If abso-
lute values and percent values of a covariate were
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All (N570) Never chronic GVHD (N521) Chronic GVHD (N549)
number (percent)
Median age in years {range} 46.3 {20-66} 47.8 {25-62} 45.6 {20-66}
Sex
Male 46 (66) 12 (57) 34 (69)
Female 24 (34) 9 (43) 15 (31)
Diagnosis
Acute leukemia 39 (56) 12 (57) 27 (55)
Chronic myelogenous leukemia 13 (19) 5 (24) 8 (16)
Malignant lymphoma 9 (13) 1 (5) 8 (16)
Other† 9 (13) 3 (14) 6 (12)
Disease status at transplantation ‡
Standard risk 48 (69) 18 (86) 30 (61)
High risk 22 (31) 3 (14) 19 (39)
Conditioning regimen
Myeloablative conditioning 46 (66) 12 (57) 34 (69)
Reduced intensity conditioning 24 (34) 9 (43) 15 (31)
Stem cell donors
Related 35 (50) 13 (62) 22 (45)
Unrelated 35 (50) 8 (38) 27 (55)
HLA-identical 67 (96) 21 (100) 46 (94)
HLA-mismatched 3 (4) 0 3 (6)
Stem cell source
Bone Marrow 22 (31) 10 (48) 12 (25)
Peripheral Blood Stem Cells 48 (69) 11 (52) 37 (75)
Median number of CD34 1 cells x106 /kg
transplanted {range}
5.5 {0.7-14.0} 4.4 {1.2-8.4} 5.4 {0.7-14.0}
Post-transplant immunosuppressive
prophylaxis
Cyclosporine only 2 (3) 1 (5) 1 (2)
Cyclosporine-Methotrexate 49 (70) 12 (57) 37 (76)
Cyclosporine-Mycophenolate Mofetil 19 (27) 8 (38) 11 (22)
Acute GVHD
Grade 0 38 (54) 15 (71) 23 (47)
Grades I-II 16 (23) 2 (10) 14 (29)
Grades III-IV 16 (23) 4 (19) 12 (24)
*GVHD indicates graft-versus-host-disease.
†Other diagnosis includes aplastic anemia, myelodysplastic syndrome, chronic lymphocytic leukemia, and myeloma.
‡Patients with standard risk were defined as those who received a transplant during the first or second complete remission of acute leukemia or in
the first chronic phase of chronic myelogenous leukemia. Patients with high risk were those with myelodysplastic syndrome and a more advanced
stage of acute leukemia or chronic myelogenous leukemia than those with standard risk.available as different variables, then these covariates
were entered into separate multiple logistic models.
If continuous variables showed interaction with an-
other variable, they were centered by the median. All
dichotomous variables were dummy-coded by 0 and
1. In the multiple logistic regression analysis, a back-
ward selection was conducted with a removal P-value
of .10 calculated with the Wald statistic. The results
of the logistic regression analyses are presented as
odds ratio (OR) and 95% confidence interval (95%
CI). P-values below .05 were considered significant.
RESULTS
Characteristics of the Patients and Infectious
Complications
Among our 70 patients, 21 had never experienced
cGVHD (never cGVHD); 49 had experiencedcGVHD including 14 with complete resolution of
cGVHD (resolved cGVHD); and 35 patients had par-
tial organ response or progression of cGVHD (active
cGVHD) at study entry as previously defined [29].
All patients showed complete multilineage donor
chimerism as determined by standard VNTR analysis
a median of 47.6 (range, 5-150) months after HSCT.
In addition, FISH analysis confirmed full donor chi-
merism of sorted B lymphocytes in 6 patients after
sex-mismatched transplantation. No significant differ-
ence between overall B cell numbers; absolute CD41
and CD81T cell counts; NK cell; monocyte and over-
all leukocyte counts was evident in the active cGVHD
group when compared to the never and resolved
cGVHD groups. However, granulocyte counts were
significantly elevated in the active and resolved
cGVHD groups, which might reflect the use of
steroids.
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cGVHD (but within the first year after unrelated do-
nor HSCT) were under antibiotic prophylaxis target-
ing encapsulated bacteria and Pneumocystis carinii.
Whereas no bacterial, viral, and fungal infection
were observed beyond 12 months of HSCT in patients
never experiencing cGVHD, markedly more of these
infectious episodes were documented in patients with
active cGVHD. These included clinically defined up-
per respiratory tract infection (n519), pneumonia
(n57), clostridium difficile gastroenteritis (n53), E.
coli cystitis (n52), cytomegalovirus (CMV) reactiva-
tion (n53), herpes simplex viral infection (n56), can-
dida albicans stomatitis (n53), candida glabrata
gastroenteritis (n52), and aspergillus flavus pneumo-
nia (n51). Patients with active cGVHD also hadmark-
edly more infectious episodes of any kind throughout
their follow-up when assigned to the subgroup with se-
vere infections (CTC grades III-IV). Between patients
never experiencing cGVHD, ones with resolved
cGVHD, and ones with active cGVHD, no significant
differences were observed concerning the incidence of
severe infectious complications after HSCT.
Table 2. Characteristics of chronic GVHD Patients
chronic GVHD (N549)
number (percent)
Onset type of chronic GVHD
De novo 24 (49)
Quiescent 15 (31)
Progressive 10 (20)
Activity of chronic GVHD at study entry
Resolved 14 (29)
Active* 35 (71)
Chronic GVHD organ involvement at
study entry
Skin 20 (41)
Eyes 18 (37)
Oral mucosa 16 (33)
Liver 11 (22)
Lungs 11 (22)
Musculosceletal 4 (8)
none, 1 or 2 organs 35 (71)
. 2 organs 14 (29)
Median duration of immunosuppressive
therapy for chronic GVHD in months
{range}
36 (3-104)
Immunosuppressive therapy at study entry
None 12 (25)
Cyclosporin/FK506 14 (29)
Cyclosporin/FK506 1 extracorporeal
photoimmunotherapy 1/- Steroids
9 (18)
Cyclosporin/FK506 1 Steroids 1/-
Mycophenolate mofetil
5 (10)
Other† 9 (18)
*Presence of at least 1 diagnostic clinical sign of chronic GVHD as
defined by the NIH Consensus 2 and partial response or worsening
to therapy as previously defined by Pavletic et al. [29]
†Other include various combinations of above mentioned treatment
regimens.Immature/Transitional CD191/CD21- B
Lymphocytes are Significantly Increased in Active
cGVHD Patients with Severe Infections and
Multiple Infectious Episodes
Whereas patients of the never cGVHD group and
healthy donors (data not shown) had low numbers of
immature/transitional circulating CD191CD21- B
cells (7.4% 1/- 7.5%), this compartment was consid-
erably enlarged among active cGVHD patients
(7.4% 1/- 7.5% vs 11.1% 1/- 11.9% and 20.4 vs.
34.8 cells/mL) (Table 3 and Figure 2, P5.074).
Most interestingly, in the overall patient sample,
elevated numbers (.15%) of immature/transitional
CD191CD21- B lymphocytes were significantly asso-
ciated with occurrence of severe infections (P5.003).
When we applied the mean value, plus one standard
deviation of never cGVHD (ie 15% as the cut-off
level), the subgroup analysis revealed that all patients
(9/9) with active cGVHD andmore than 15% of circu-
lating CD191CD21- B lymphocytes had experienced
severe infections (CTC grades III-IV). In contrast,
only 7 of 26 patients (27%) with active cGVHD and
#15% of circulating CD191CD21- B lymphocytes
had a history of severe infections. The observed asso-
ciation between high numbers of CD191/CD21- B
cells and severe infectious complications among active
cGVHD patients was highly significant (P 5 .00016).
Figure 1. Time from HSCT until analysis of B cell subpopulations.
On the X axis, the 3 patient groups consisting of never cGVHD (no),
resolved (res.) and active (act.) cGVHD at the time of first flow cyto-
metric exam are shown; on the Y axis, the months from day 0 of he-
matopoietic stem cell transplantation (HSCT) until first B cell
analysis. Bars represent mean values in each group. P-value between
patient groups never cGVHD and active cGVHD was calculated by
two-tailed Students t-test.
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CD191/CD21- B lymphocytes in subgroups of patients
No. of patients Percentage of CD191 Absolute cell number/mL
All patients 70 10.6 29.3
Never cGVHD 21 7.4 20.4
Resolved cGVHD 14 14.1 29.0
Active cGVHD 35 11.1 34.8
P 5 0.678† P 5 0.112†
Number (%) of patients with infectious complications
No. of patients Infections CTC grades 0-II* Infections CTC grades III-IV*
All patients 70 41 (59) 29 (41)
Never cGVHD 21 13 (62) 8 (38)
Resolved cGVHD 14 7 (50) 7 (50)
Active cGVHD 35 19 (54) 16 (46)
P 5 1. 0†
Severe infectious complications correlate with elevated numbers of CD191/CD21- B lymphocytes
No. of patients Infections CTC grades 0-II* no. (%) Infections CTC grades III-IV* no. (%)
All patients .15% CD191/21- 15 3 (20) 12 (80)
All patients # 15% CD191/21- 55 36 (66) 19 (34)
P 5 .003
Active cGVHD patients .15% CD191/
21-
9 0 (0) 9 (100)
Active cGVHD # 15% CD191/21- 26 19 (73) 7 (27)
P 5 .00016
Never and resolved cGVHD .15%
CD191/21-
6 3 (50) 3 (50)
Never and resolved cGVHD # 15%
CD191/21-
29 17 (59) 12 (41)
P 5 1.0
All Patients ‡ H-J bodies 1 15 4 (27) 11 (73)
All patients H-J bodies - 53 35 (66) 18 (34)
P 5 .009
*Infection Module, National Cancer Institute - Common Toxicity Criteria (CTC) Manual. [28]
†P value showing no significant difference between active- and never1resolved cGVHD subgroups.
‡2 patients with splenectomy before HSCT were excluded from the analysis.In contrast, in patients in the never or resolved
cGVHD group, no significant association between
high CD191CD21- B lymphocyte numbers and severe
infections was observed (Table 3).
In addition, significantly more clinically defined
(P5 .0049) and fungal (P5 .0057) infectious episodes
were observed in patients with active cGVHD, and
more than 15% of circulating CD191CD21- B lym-
phocytes 1 to 24 months and 1 to 36 months (P 5
.036 and P 5 .039) after HSCT compared to active
cGVHD patients with #15% of circulating CD 119
CD21- B lymphocytes.
The significance of elevated CD191CD21- B lym-
phocytes as an independent factor for susceptibility to
severe infections in active cGVHD patients was con-
firmed in logistic regression analysis with an OR of
1.495 (95% CI 1.118-1.999, P 5 .007). Of note, ste-
roid use was not more frequent in patients with high
CD191CD21- B lymphocyte numbers or severe infec-
tions (P 5 .16 and P 5 .11).When we analyzed the expression of the activation
marker CD69, no increase was observed in any patient
in the study.
Memory B Lymphocyte (CD191/CD271) Numbers
are Significantly Lower in Patients with Active
cGVHD
To assess the homeostasis of mature B cell subsets
in cGVHD, we examined CD191 B cell memory
subpopulations (non-class-switched IgD1 cells and
class-switched IgD- cells) [33] and stratified patients
according to cGVHD activity and infectious compli-
cations. We found significantly lower relative and
absolute numbers of non-class-switched CD271IgD1
memory B cells (Figure 3A and Table 4) in patients
with active cGVHD compared to patients who never
experienced cGVHD (2.8 versus 4.7%, P 5 .002;
12.0 versus 22.1 cells/mL, P5.047). Similar results
were obtained for class-switched CD271/IgD- mem-
ory B cells in patients with active cGVHD compared
214 H. T. Greinix et al.Figure 2. Phenotype of circulating B cells after HSCT.Whole blood cells were stained with the indicated fluorochrome conjugated mAbs. Sub-
sequently, red blood cells were lysed and the remaining nucleated cells were analyzed by flow cytometry. CD191 peripheral blood B lymphocytes
were gated and the differential expression of surface IgD, CD27 and CD21 was assessed in healthy donors (HD) and patients with active (active
cGVHD) or without (no cGVHD) cGVHD. Results are expressed as two-parameter dot-plots and are representative for the individuals within
the same group. Numbers indicate the percentage of positive cells in the respective area.to patients who never experienced cGVHD (3.1 versus
6.5%, P 5 .001; 10.1 versus 27.2 cells/mL, P 5 .023)
(Figure 3B and Table 4).
When applying the mean value of 3 percent as the
cut-off level for low memory B cells, as observed in the
active cGVHD group, 65% (23/35) and 71% (25/35)of patients with active cGVHD fulfilled these criteria.
This was in significant contrast to only 29% (6/21) and
9% (2/21) of patients who never experienced cGVHD
(Table 4).
Moreover, the ratio formed between immature/tran-
sitional B lymphocytes and memory B cell subsetsFigure 3. Significantly lower numbers of memory B lymphocytes in patients with active cGVHD.Whole blood cells were stained for the expres-
sion of CD19, IgD, and CD27 as exemplified in Figure 3. After HSCT, patients were assigned to various groups: 35 patients with active (act.–
partial response or progression) and 14 with resolution (res.–complete response) of cGVHD according to published criteria. Another 21 patients
had never experienced cGVHD (no) until study entry. In patients analyzed serially, only the first time point was included in this figure. Diamonds
represent the percentage of non-class-switched (A) and class- switched (B)memory B lymphocytes for each patient. Statistical analysis was per-
formed by the paired Student’s t-test, and P values are indicated. The 2 outliers in A have been excluded from calculations.
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CD271 *3% of CD271/CD191
Percentage of CD191 Absolute cell number /mL No. of patients (%)
IgD1 IgD- IgD1 IgD- IgD1 IgD- Ratio between CD21- and CD271IgDall
Never cGVHD (N521) 4.7 6.5 22.1 27.2 6 (29) 2 (9) 0.85 ± 1.14
Resolved cGVHD (N514) 4.8 7.7 10.9 17.5 2 (14) 2 (14) 1.25 ± 0.83
Active cGVHD (N535) 2.8 3.1 12.0 10.1 23 (65) 25 (71) 1.99 ± 1.52
P Value .002† .001† .047† .023† .012‡ \.001‡ .0046††
*Percentages as calculated from the overall numbers of CD 191 B cells.
††P Value was calculated by comparing the ratios of the indicated B-lymphocyte subsets in the subgroups of active and never chronic GVHD.
†P Values were calculated comparing percentages and absolute numbers of B lymphocyte subsets in the subgroups of active and never cGVHD.
‡P Values were calculated by comparing the number of patients in the subgroups of active and never cGVHD.confirms thediscriminationof the3groupsofGVHDpa-
tients (Table 4). No significant correlation between
incidence and severity of infectious complications of pa-
tients (with or without active cGVHD activity) and low
memory B cell numbers was evident. In addition, steroid
usewasnotmore frequent inactive cGVHDpatientswith
decreased CD191CD271IgD1 or CD191CD271IgD-
B lymphocytes (P5 1.0 and P5 .66).
Serial Analyses
Among the 36 patients monitored serially both for
cGVHD activity and homeostasis of B cell subsets, 25
patients had active cGVHD at first assessment of B cell
subpopulations. Twelve of them did not respond to
immunosuppressive therapy during the study period
and, in some of these patients, CD21-/CD271IgDall
ratios remained markedly elevated (Figure 4A) com-
pared to the groups with no cGVHD or partial overall
response (defined as improvement in a measure for at
least one organ without progression in measures for
any other organ) [29]. In the 13 patients with active
cGVHD achieving partial overall response during
the study period, a decrease in CD21-/CD271IgDall
ratios was observed as shown in Figure 4B. The 11 pa-
tients without cGVHD at study entry remained low
with their CD21 -/CD271IgDall ratio and had no
chronic GVHD activity during their time in the study
(Figure 4C).
Other Predictors of Infectious Complications are
Only Weakly Associated with Active cGVHD
A hallmark of cGVHD is functional asplenia with
the possible appearance of HJ bodies in the circulation
[15]. Therefore, we correlated the presence of HJ bod-
ies in blood smears with the patients’ susceptibility to
severe infections. In all eligible patients, the presence
of HJ bodies correlated to some degree with suscepti-
bility to severe infections (Table 3, P 5 .009). Al-
though HJ bodies were more frequent in patients
with active cGVHD (11/35; 31%) than in the other
two groups (4/33, 12%), no significant correlation be-tween the presence of HJ bodies and infectious com-
plications was observed in either of the cGVHD
subgroups (P 5 .065 and P 5 .28).
Immunoglobulins are the major effector molecules
ofB lymphocytes and Ig serum levels canbe taken as sur-
rogate-markers for B lymphocyte function. Hypogam-
maglobulinemia is not uncommon after HSCT [33].
Indeed, 13 of 70 patients (19%) had low IgG serum
levels (\ 7g/L) including 9 of 35 (26%) with active
cGVHD. Both in the overall group of patients and in
the subgroup with active cGVHD, hypogammaglobuli-
nemia did not significantly correlate with incidence and
severity of infections. This clearly implies that an ele-
vated number of immature/transitional CD191/
CD21- B lymphocytes is a stronger predictor for suscep-
tibility to infection than is hypogammaglobulinemia.
Multiple logistic regression analysis revealed
a mild significant association between a decreased
CD4/CD8 ratio and severe infections (OR 0.308,
95%CI 0.106-0.895, P 5 .031) in the overall patient
group, however, this phenomenon was not from cellu-
lar deficiency. Instead, it reflected the disproportional
increase of CD8 T cell counts as observed in active
cGVHD patients. Along those lines, no significant dif-
ferences of CD4/CD8 ratios were observed between
active cGVHD patients with or without severe infec-
tions. In addition, neither granulocyte counts nor
CD41 and CD81 T lymphocyte counts, NK cell,
monocyte and leukocyte counts correlated with sever-
ity of infections in these patients.
DISCUSSION
GVHD selects the lymphoid system as a target or-
gan [11] leading to lymphoid hypocellularity and atro-
phy as characteristic histologic hallmarks of severe
GVHD. The primary cause of NRM associated with
cGVHD is infection. T and B lymphocyte deficiencies
are thought to play a role in the susceptibility of trans-
plant recipients to infections [34]. Here, we demon-
strate a severe disturbance of B cell homeostasis in
a group of patients with active cGVHD seen as
216 H. T. Greinix et al.Figure 4. Serial analyses of B cell subpopulations. On the X-axis, the time on study in months calculated from first assessment of B cell subsets is
shown; on the Y-axis, the ratio formed between immature/transitional B lymphocytes and memory B cells is shown. A represents patients with
active cGVHD not responding or progressing during study (n512); B shows patients with active cGVHD achieving a partial overall response
during study (n513); and C shows patients without cGVHD (n511).significantly elevated numbers of immature/transi-
tional CD21- B cells and low CD271 memory B cell
counts. Whereas severe infectious complications
were not significantly more frequent in all patients
with active cGVHD, the patients with more than
15% of circulating immature/transitional CD191/
CD21- B lymphocytes (ie those having a CD191/
CD21- percentage that lies above the mean plus 1 stan-
dard deviation of never cGVHD) in the subgroup of
active cGVHD had significantly more severe infec-
tions [28]. In addition, significantly more clinically de-
fined and fungal infectious episodes up to 36 months
after HSCT were observed in patients with active
cGVHD and elevated immature/transitional
CD191/CD21- B lymphocyte numbers. Of note, sup-
portive care and anti-infectious strategies were similar
in the subgroups studied. Logistic regression analysis
confirmed elevated immature/transitional CD191/
CD21- B lymphocyte counts as independent risk fac-
tors for severe infections in active cGVHD.Storek et al [34] reported a significant association
of low B cell and monocyte counts on day 80 with an
increased rate of infections between days 100 and
365 after allogeneic marrow transplantation. In our
study, no significant differences in CD41 and CD81
lymphocyte counts, NK cell, monocyte and overall B
lymphocyte numbers were seen between patients
with or without severe infections. Since the majority
of our patients, however, were analyzed more than 1
year after HSCT, our patient cohort is not comparable
and the role of immune re-constitution on HSCT re-
cipient defense against microorganisms cannot be
evaluated in our pilot study. Following allogeneic
HSCT, grafted donor-derived precursor cells must re-
capitulate the ontogeneic process of B-lymphopoiesis.
An early post-transplant period of severely depressed
blood B cell counts is followed by a progressive nor-
malization of B-cell numbers within the first year
after HSCT [35,36]. However, the development of
acute GVHD (aGVHD) or cGVHD after HSCT is
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immunodeficiency with decreased or absent marrow
B-cell precursors [5,37,38]. Thus, Storek et al [5] ob-
served an 18-fold lower number of B cell precursors
on day 365 after HSCT in patients with extensive
cGVHD.
To date, reports on the reconstitution of B cell
subpopulations after allogeneic HSCT are sparse. Re-
cently, Cuss et al [39] observed a 4- to 5-fold increase
in immature/transitional B cell numbers and below 5%
memory B cells compared to normal donors in patients
at 2-3 mos after HSCT. In the follow-up period, im-
mature/transitional B cell numbers declined, whereas
memory B cell counts increased, indicating that in
post-transplant patients immature/transitional B cells
were generated early and were replaced over time by
memory B cells. Similarly, Avanzini et al [40] assessing
B lymphocyte reconstitution in children observed
a slow recovery of memory B cells up to 24 months af-
ter HSCT. Immature/transitional B lymphocytes lack
CD21 and classical activation or memorymarkers such
as CD69 [23] and CD27, indicating that these cells
most probably have not responded to antigens re-
cently. They typically co-express CD10 and high levels
of CD38. CD21 is exclusively expressed on mature B
cells, where it forms a signal-transduction complex
that also includes CD19, CD81, and CD225. Thus,
CD21-negativity serves as an excellent marker for im-
mature/transitional B cells [21,22]. Whereas Cuss et al
[39] observed replacement of immature/transitional B
cells by memory B cells during immune reconstitution
in HSCT patients, in our active cGVHD subgroup
circulating memory B lymphocytes remained low and
the expansion of immature/transitional B cells was
prominent. These findings indicate an impairment of
the immune system, which is reminiscent of other pri-
mary or acquired immunodeficiencies and distinct au-
toimmune diseases. Along those lines, Warnatz et al
[41] reported an elevation of immature/transitional
CD21- B cells and low class-switched memory B cell
counts in patients with common variable immunodefi-
ciency. A high percentage of CD21- B cells has been
observed in the circulation ofHIV-infected individuals
with advanced disease [25] and in SLE patients [23]. It
remains to be shown whether the observed disturbance
of the B cell compartments is caused by direct interfer-
ence with B cell function or if it is secondary to subtle
changes within distinct T cell compartments. Un-
doubtedly, the development of memory B cells is
closely linked to the germinal center (GC) reaction,
which takes place in secondary lymphoid organs
upon encounter with antigen. The finding that signif-
icantly fewer memory B cells are present in cGVHD
patients might argue for a disturbed GC reaction in
cGVHD. Several possible reasons for a disturbed
GC reaction are known. Mutations in the CD40 or
CD40 ligand gene (CD154) [42, 43]; defects of the tu-mor necrosis factor alpha (TNF-a) family and its
receptors [44]; an impaired expression of co-stimula-
tory molecules such as CD86 [45] or ICOS [46]: all in-
terfere significantly with the formation and function of
GCs. Thus, a concerted action between T and B cells
within the reticular network of lymph nodes is essen-
tial for the transition of a primary into a secondary
follicle. Currently, however, we do not have any indi-
cations that one of the above cited gene defects are
causative in the immunopathology of cGVHD. Apart
from non-functional receptor-ligand pairs, deteriora-
tion of whole cellular subsets might influence distinct
B cell compartments in an individual. Both essential
and HIV-induced CD4 lymphocytopenia were found
to be associated with the expansion of immature B lym-
phocytes, a phenomenon that is directly correlated
with elevated serum interleukin-7 (IL-7) levels [25,
47]. As pointed out by the authors, it was, however, dif-
ficult to determine whether the expansion of immature
B cells was a direct response to the increased levels of
IL-7 or an indirect effect that emanated from the loss
of CD4 T cells. Evidence for a direct effect of IL-7
on B cells comes from the observation that IL-7 treat-
ment of cancer patients leads to a clear increase in im-
mature progenitor B cells within the bone marrow
[48]. In our pilot study, there were no significant dif-
ferences in the CD4 cell counts between patients
with cGVHD and those without and resolved disease.
It will be interesting, therefore, to examine IL-7 serum
levels in our patient sample and to correlate them with
immature B cell numbers in the future.
To our knowledge, this is the first report indicating
a correlation of disturbed B cell homeostasis and sus-
ceptibility to infections in cGVHD. Monitoring the
frequency of immature/transitional as well as memory
B cells may provide a means of assessing the immuno-
competence of individuals after HSCT. Interestingly,
immature/transitional B cells appear to represent
a checkpoint where auto-reactive B cells are removed
from the peripheral population [49]. Aberrations at
this stage of B cell development (which are possibly
also promoted directly by high levels of BAFF [19])
may contribute to the appearance of circulating auto-
reactive B cells as has been shown in mouse models
for SLE [50] and collagen-induced arthritis [51]. Aber-
rations at this stage of B cell development might even
directly contribute to the pathogenesis of cGVHD [52,
53]. Further investigation of immature/transitional B
cells could improve our knowledge of how alterations
to the processes of B cell reconstitution after HSCT
may precipitate immunodeficiency or autoimmunity.
Such knowledge might also lead to strategies for en-
hancing the differentiation of immature B cells into
mature effector cells in vivo, which might alleviate
the B cell deficiency of such individuals.
To date, a limited number of biomarkers for
cGVHD have been evaluated [54] despite the clear
218 H. T. Greinix et al.need for assessment tools that are dynamic and allow
direct investigation of effector cells of the immune sys-
tem. Our preliminary data obtained from the studied
patients serially support a trend towards normalization
of B cell homeostasis in patients with decreasing
cGVHD activity whereas ongoing active cGVHD
was associated with continuous B cell disturbance in
the circulation. Thus, an expansion of immature/tran-
sitional B cells combined with low memory B cell
numbers could serve as novel biomarkers both for
cGVHD activity, and for its impact on the immune
system. We are aware of the limitations of our retro-
spective study, including the potential impact of
concomitant immunosuppressive therapies on pro-
longation of immunodeficiency and the patient hetero-
geneity with regard to duration of cGVHD and
follow-up times. Therefore, a prospective study of
consecutive patients after HSCT that assesses both
time to immune reconstitution and the impact of
cGVHD on the immune system is highly warranted.
In conclusion, flow cytometric evaluation of B
lymphocyte subsets allows assessment of activity of
cGVHD and the perturbation of the circulating B lym-
phocyte compartments can help to identify cGVHD
patients with severe immunodeficiency seen as in-
creased susceptibility to severe infections.
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